| Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin L Borsi, E Balza, M Bestagno, P Castellani, B Carnemolla, A Biro, ... International journal of cancer 102 (1), 75-85, 2002 | 423 | 2002 |
| A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. B Carnemolla, E Balza, A Siri, L Zardi, MR Nicotra, A Bigotti, PG Natali The Journal of cell biology 108 (3), 1139-1148, 1989 | 421 | 1989 |
| Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform D Neri, B Carnemolla, A Nissim, A Leprini, G Querzè, E Balza, A Pini, ... Nature biotechnology 15 (12), 1271-1275, 1997 | 397 | 1997 |
| Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix B Carnemolla, L Borsi, E Balza, P Castellani, R Meazza, A Berndt, ... Blood, The Journal of the American Society of Hematology 99 (5), 1659-1665, 2002 | 355 | 2002 |
| Selective targeted delivery of TNFα to tumor blood vessels L Borsi, E Balza, B Carnemolla, F Sassi, P Castellani, A Berndt, ... Blood 102 (13), 4384-4392, 2003 | 307 | 2003 |
| A high-affinity human antibody that targets tumoral blood vessels L Tarli, E Balza, F Viti, L Borsi, P Castellani, D Berndorff, L Dinkelborg, ... Blood, The Journal of the American Society of Hematology 94 (1), 192-198, 1999 | 266 | 1999 |
| Transforming growth factor β regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts E Balza, L Borsi, G Allemanni, L Zardi FEBS letters 228 (1), 42-44, 1988 | 235 | 1988 |
| Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy L Mortara, E Balza, A Bruno, A Poggi, P Orecchia, B Carnemolla Frontiers in Immunology 9, 424754, 2018 | 118 | 2018 |
| Redox remodeling allows and controls B-cell activation and differentiation R Vené, L Delfino, P Castellani, E Balza, M Bertolotti, R Sitia, A Rubartelli Antioxidants & redox signaling 13 (8), 1145-1155, 2010 | 109 | 2010 |
| Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different … E Balza, L Mortara, F Sassi, S Monteghirfo, B Carnemolla, P Castellani, ... Clinical cancer research 12 (8), 2575-2582, 2006 | 104 | 2006 |
| The Alternative Splicing Pattern of the Tenascin-C Pre-mRNA Is Controlled by the Extracellular pH (∗) L Borsi, E Balza, B Gaggero, G Allemanni, L Zardi Journal of Biological Chemistry 270 (11), 6243-6245, 1995 | 103 | 1995 |
| Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin E Balza, A Siri, M Ponassi, F Caocci, A Linnala, I Virtanen, L Zardi FEBS letters 332 (1-2), 39-43, 1993 | 101 | 1993 |
| Elution of fibronectin proteolytic fragments from a hydroxyapatite chromatography column: a simple procedure for the purification of fibronectin domains L Zardi, B Carnemolla, E Balza, L Borsi, P Castellani, M Rocco, A Siri European journal of biochemistry 146 (3), 571-579, 1985 | 97 | 1985 |
| Lack of specificity of endoglin expression for tumor blood vessels E Balza, P Castellani, A Zijlstra, D Neri, L Zardi, A Siri International journal of cancer 94 (4), 579-585, 2001 | 95 | 2001 |
| Inflammation, DAMPs, tumor development, and progression: a vicious circle orchestrated by redox signaling P Castellani, E Balza, A Rubartelli Antioxidants & redox signaling 20 (7), 1086-1097, 2014 | 81 | 2014 |
| Tumor targeting potential of the monoclonal antibody BC‐1 against oncofetal fibronectin in nude mice bearing human tumor implants G Mariani, A Lasku, E Balza, B Gaggero, C Motta, LD Luca, A Dorcaratto, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1997 | 68 | 1997 |
| Human Tenascin Gene: STRUCTURE OF THE 5′-REGION, IDENTIFICATION, AND CHARACTERIZATION OF THE TRANSCRIPTION REGULATORY SEQUENCES (∗) R Gherzi, B Carnemolla, A Siri, M Ponassi, E Balza, L Zardi Journal of Biological Chemistry 270 (7), 3429-3434, 1995 | 68 | 1995 |
| Tenascin and fibronectin distribution in human normal and pathological synovium. M Cutolo, M Picasso, M Ponassi, MZ Sun, E Balza The Journal of Rheumatology 19 (9), 1439-1447, 1992 | 66 | 1992 |
| Characterization of synovial fluid fibronectin from patients with rheumatic inflammatory diseases and healthy subjects B Carnemolla, M Cutolo, P Castellani, E Balza, S Raffanti, L Zardi Arthritis & Rheumatism: Official Journal of the American College of …, 1984 | 66 | 1984 |
| Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFα E Balza, B Carnemolla, L Mortara, P Castellani, D Soncini, RS Accolla, ... International journal of cancer 127 (1), 101-110, 2010 | 65 | 2010 |
Castellaninatinal cancer institute genoaVerified email at istge.it
